
--- Page 1 ---
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
A. 510(k) Number:
k050625
B. Purpose for Submission:
Modification of the manufacturer’s existing cleared device (Varelisa® ReCombi
ANA Profile) by replacing the Sm antigen with the Sm[D] antigen (k042629)
C. Measurand:
Anti-Sm[D] antibodies
D. Type of Test:
Qualitative Enzyme Immunoassay (EIA)
E. Applicant:
Sweden Diagnostics (Germany) GmbH
F. Proprietary and Established Names:
Varelisa® ReCombi ANA Profile
G. Regulatory Information:
1. Regulation section:
21 CFR 866.5100 Antinuclear Antibodies Immunological
2. Classification:
II
3. Product code:
LJM, Antinuclear antibody, Antigen and Control
4. Panel:
Immunology 82
H. Intended Use:
1. Intended use(s):
The Varelisa ® ReCombi ANA Profile EIA kit is designed for the qualitative
determination of eight antinuclear antibodies in human serum or plasma to aid in
the diagnosis of SLE (systemic lupus erythematosus), scleroderma (progressive
systemic sclerosis and CREST syndrome), MCTD (mixed connective tissue
disease), SS (Sjogren’s syndrome) and polymyositis/dermatomyositis. The
Varelisa ReCombi ANA Profile individually detects antibodies against dsDNA,
U1RNP (RNP 70, A, C), SmD, SS-A/Ro (52 kDa, 60 kDa), SS-B/La, Scl-70,
CENP-B and Jo-1. For in vitro diagnostic use only.
2. Indication(s) for use:
Same as intended use.
3. Special conditions for use statement(s):
For prescription use only.
4. Special instrument requirements:
Microplate reader capable of measuring OD at 450nm.
I. Device Description:
For detection of Sm[D], the modified assay contains microplate wells coated with
synthetic peptides (Sm[D]) in place of Sm. All other reagents are the same as the
previously cleared device.

--- Page 2 ---
J. Substantial Equivalence Information:
1. Predicate device name(s):
Varelisa® ReCombi ANA Profile (No. 12996) and Varelisa® Sm Antibodies
2. Predicate 510(k) number(s):
k993109 and k042629
3. Comparison with predicate:
Similarities
Item New Device Predicate Device
Indications for use To aid in the diagnosis of SLE Same
(systemic lupus
erythematosus), scleroderma
(progressive systemic
sclerosis and CREST
syndrome), MCTD (mixed
connective tissue disease), SS
(Sjogrens syndrome), and
polymyositis/dermatomyositis.
Technology ELISA Same
Assay Format Qualitative Same
Sample dilution 1:101 dilution Same
Enzyme-Conjugate Rabbit anti-human IgG Same
Horseradish Peroxidase
Substrate, wash buffer Same Same
and stop solution
Incubation times 30, 30 and 10 minutes Same
Platform 96 well microtitre plates Same
Result interpretation Negative: <1.0 Same
(ratio compared to cut- Equivocal: 1.0 – 1.4
off control) Positive: >1.4
Matrix Serum and plasma (EDTA, Same
citrate)
Antigens dsDNA, U1RNP (RNP 70, A, Same
C), SS-A/Ro (52 kDa, 60
kDa), SS-B/La, Scl-70,
CENP-B and Jo-1
Differences
Item Device Predicate
Antigen Synthetic human Sm[D] Sm antigen purified from
peptide. calf thymus.
Sample diluent 20mL 5X Concentrate 100 mL ready to use
K. Standard/Guidance Document Referenced (if applicable):
None referenced.
L. Test Principle:
The Varelisa ReCombi ANA Profile is an indirect noncompetitive enzyme

[Table 1 on page 2]
Similarities										
	Item		New Device						Predicate Device	
Indications for use			To aid in the diagnosis of SLE
(systemic lupus
erythematosus), scleroderma
(progressive systemic
sclerosis and CREST
syndrome), MCTD (mixed
connective tissue disease), SS
(Sjogrens syndrome), and
polymyositis/dermatomyositis.					Same		
Technology			ELISA					Same		
Assay Format			Qualitative					Same		
Sample dilution			1:101 dilution					Same		
Enzyme-Conjugate			Rabbit anti-human IgG
Horseradish Peroxidase					Same		
Substrate, wash buffer
and stop solution			Same					Same		
Incubation times			30, 30 and 10 minutes					Same		
Platform			96 well microtitre plates					Same		
Result interpretation
(ratio compared to cut-
off control)			Negative: <1.0
Equivocal: 1.0 – 1.4
Positive: >1.4					Same		
Matrix			Serum and plasma (EDTA,
citrate)					Same		
Antigens			dsDNA, U1RNP (RNP 70, A,
C), SS-A/Ro (52 kDa, 60
kDa), SS-B/La, Scl-70,
CENP-B and Jo-1					Same		
Differences										
	Item			Device			Predicate			
Antigen			Synthetic human Sm[D]
peptide.			Sm antigen purified from
calf thymus.				
Sample diluent			20mL 5X Concentrate			100 mL ready to use				

--- Page 3 ---
immunoassay for the individual qualitative determination of dsDNA, U1RNP (RNP
70, A, C), Sm[D], SS-A/Ro (52 kDa, 60 kDa), SS-B/La, Scl-70, CENP-B and Jo-1
antibodies in serum and plasma. The wells of a microplate are coated with human
recombinant nuclear antigens, synthetic peptides (SmD) or plasmid DNA. Antibodies
specific for the nuclear antigens are present in a patient sample bind to these nuclear
antigens. In a second step the enzyme labeled second antibody (conjugate) binds to
the antigen-antibody complex which leads to the formation of an enzyme labeled
conjugate-antibody-antigen complex. The enzyme labeled antigen-antibody complex
converts the added substrate to form a colored solution. The rate of color formation
from the chromogen is a function of the amount of conjugate complexed with the
bound antibody and is proportional to the initial concentration of the respective
antibodies in the patient sample. The results are read spectrophotometrically and are
interpreted by comparison to a cut-off calibrator.
M. Performance Characteristics (if/when applicable):
1. Analytical performance:
Data presented are for all eight analytes.
a. Precision/Reproducibility:
i. Study design: Three samples (equivocal, low positive, high positive) per
analyte were analyzed in 5 runs, with 5 replicates per run. Calibrator and
control were analyzed in triplicates. Within one day one operator carried
out the analyses.
ii. Results/Acceptance criteria: Target values for the study were set at variance
intra assay = <12% and inter assay = <8%. Intra-assay variation ranged
from 1.8% to 7.9% and inter-assay variation ranged from 1.0% to 7.2%
and all were within the target values.
Mean Variability (CV %)
Analyte Sample
(Ratio) Intra-assay Inter-assay
dsDNA equivocal 1.2 2.4 3.9
low positive 2.3 3.4 4.3
high positive 3.0 2.4 5.9
U1RNP equivocal 1.4 3.3 2.5
low positive 2.0 3.6 3.8
high positive 3.4 2.1 7.2
Sm[D] equivocal 1.1 2.3 2.3
low positive 1.9 3.7 5.4
high positive 3.3 1.8 3.2
SS-A/Ro equivocal 1.1 3.9 1.9
low positive 2.7 3.0 1.3
high positive 4.5 3.4 3.3
SS-B/La equivocal 1.3 2.7 2.5
low positive 1.9 2.2 5.6
high positive 3.1 1.9 2.9
Scl-70 equivocal 1.2 3.9 4.5
low positive 2.5 4.1 5.6
high positive 3.9 3.1 4.5
CENP equivocal 1.1 2.8 1.0
low positive 1.8 3.2 3.4
high positive 3.3 3.2 4.0
Jo-1 equivocal 1.3 2.2 2.8
low positive 2.1 7.9 3.1
high positive 2.7 3.8 5.0

[Table 1 on page 3]
Analyte	Sample	Mean
(Ratio)	Variability (CV %)	
			Intra-assay	Inter-assay
dsDNA	equivocal	1.2	2.4	3.9
	low positive	2.3	3.4	4.3
	high positive	3.0	2.4	5.9
U1RNP	equivocal	1.4	3.3	2.5
	low positive	2.0	3.6	3.8
	high positive	3.4	2.1	7.2
Sm[D]	equivocal	1.1	2.3	2.3
	low positive	1.9	3.7	5.4
	high positive	3.3	1.8	3.2
SS-A/Ro	equivocal	1.1	3.9	1.9
	low positive	2.7	3.0	1.3
	high positive	4.5	3.4	3.3
SS-B/La	equivocal	1.3	2.7	2.5
	low positive	1.9	2.2	5.6
	high positive	3.1	1.9	2.9
Scl-70	equivocal	1.2	3.9	4.5
	low positive	2.5	4.1	5.6
	high positive	3.9	3.1	4.5
CENP	equivocal	1.1	2.8	1.0
	low positive	1.8	3.2	3.4
	high positive	3.3	3.2	4.0
Jo-1	equivocal	1.3	2.2	2.8
	low positive	2.1	7.9	3.1
	high positive	2.7	3.8	5.0

--- Page 4 ---
b. Linearity/assay reportable range:
Not applicable.
c. Traceability, Stability, Expected values (controls, calibrators, or methods):
Not applicable.
d. Detection limit:
The sample diluent (ready to use) was measured 30 times per analyte (10
modules of 3 different solid phase batches). Calibrator and Control were run
in singlicate. The value for the analytical sensitivity (detection limit) was
calculated as the mean of the optical densities (OD) of the sample diluent plus
three times the standard deviations (SD) (expressed in Ratios). Specifications
were: the mean plus 3 SD of the OD of the Sample Diluent should be lower
than or equal to 0.3 for each analyte. The analytical sensitivity for the eight
analytes ranged from 0.0 to 0.1. The new device met the specifications.
Standard Analytical
Mean OD
deviation Sensitivity
(n=30)
Analyte (SD) OD Ratio
dsDNA 0.005 0.005 0.021 0.1
U1RNP 0.016 0.007 0.038 0.0
Sm[D] 0.010 0.006 0.027 0.0
SS-A/Ro 0.010 0.007 0.030 0.1
SS-B/La 0.006 0.004 0.018 0.0
Scl-70 0.005 0.005 0.021 0.0
CENP 0.007 0.004 0.020 0.0
Jo-1 0.008 0.007 0.029 0.1
e. Analytical specificity:
Interference Study: Interference study data were referred to the two cleared
devices: Varelisa ReCombi ANA Profile (k993109) for the 7 antigens and
Varelisa Sm Antibodies (k042629) for the Sm[D] antigen. Data showed
heparin interfered with the measurement of Sm antibodies and lipemic,
hemolyzed or microbially contaminated samples could give poor results.
Crossreactivity to other Autoantibodies: Ten CDC International ANA Human
Reference Sera were analyzed in singlicate together with the Calibrator and
Control. The results are depicted in the table below and are comparable to the
predicate device. The new device detected the expected targets except for
sera CDC5 and CDC 10. CDC5 was found to react with in addition to Sm,
The false positive reaction with U1RNP was due to the presence of high titers
of antibodies directed against the RNP 70, A, and C in CDC 5. Western blot
analysis confirmed that CDC5 did not react with U1RNP. CDC 10 reacted
with SS-A/Ro in addition to Jo-1. The false positive result was due to the
presence of antibodies to the SS-A 52 kDa protein. The co-occurrence of
antibodies to SS-A 52 in sera of patients with idiopathic inflammatory
myopathy was described in Rutjes et al., 1997.
Panel Table: Results for the International ANA Human Reference Panel from
the Center of Disease Control (CDC)

[Table 1 on page 4]
Analyte	Mean OD
(n=30)	Standard
deviation
(SD)	Analytical
Sensitivity
OD Ratio	
dsDNA
U1RNP
Sm[D]
SS-A/Ro
SS-B/La
Scl-70
CENP
Jo-1	0.005
0.016
0.010
0.010
0.006
0.005
0.007
0.008	0.005
0.007
0.006
0.007
0.004
0.005
0.004
0.007	0.021
0.038
0.027
0.030
0.018
0.021
0.020
0.029	0.1
0.0
0.0
0.1
0.0
0.0
0.0
0.1

--- Page 5 ---
Sampl New device (U/ml)
Target
e ds U1 Sm Ro La Scl Cen Jo
CDC dsDNA & week Sm 7.1 0.5 1.0 0.2 0.0 0.1 0.2 0.1
CDC SS-B/La 0.2 0.2 0.2 2.6 3.3 0.1 0.1 0.1
CDC 3 speckled pattern, U1RNP, SS-A/Ro, 0.2 3.4 0.2 3.0 2.8 0.1 0.1 0.1
CDC 4 U1-RNP 0.2 3.3 0.2 0.1 0.0 0.1 0.1 0.1
CDC 5 Sm 0.5 2.8 4.5 0.2 0.0 0.2 0.2 0.1
CDC 6 nucleolar pattern 0.2 0.3 0.4 0.3 0.2 0.3 0.2 0.1
CDC 7 SS-A/Ro 0.6 0.1 0.2 3.5 0.1 0.1 0.1 0.1
CDC 8 CenP 0.2 0.1 0.1 0.1 0.0 0.1 4.7 0.1
CDC 9 Scl-70 0.4 0.2 0.2 0.1 0.0 3.8 0.2 0.1
CDC Jo-1 0.1 0.1 0.1 1.8 0.0 0.1 0.1 4.2
Positive results are in bold letters, disagreements with the target specificity are shaded in gray.
1 reported as weak Sm positive by Tan E.M. et al. (1999)
* SS-B/La usually does not occur without SS-A/Ro
f. Assay cut-off:
The equivocal range and the cut-off of the new device were determined by
analyzing 100 serum samples from apparently healthy Caucasian blood
donors (50 males and 50 females). The serum samples were analyzed in
singlicate together with Calibrator and Control. The specification for the
study was that the 95th percentile should lie below the lower limit of the
equivocal range for the parameter. The equivocal range of the new device
was 1.0 to 1.4. The results are depicted in the tables and histogram below.
The 95th percentile of 100 normal healthy controls ranged from 0.1 to 0.8
which met the specifications.
Statistical evaluation for n=100 Samples per analyte (*[Ratio])
Analyter dsDNA U1RNP Sm SS-A/Ro SS-B/La Scl-70 CENP Jo-1
n 100 100 100 100 100 100 100 100
Median* 0.3 0.3 0.2 0.1 0.0 0.1 0.1 0.1
Mean* 0.3 0.3 0.2 0.2 0.0 0.1 0.2 0.1
SD* 0.2 0.2 0.2 0.6 0.1 0.1 0.1 0.0
Mean + 2 SD* 0.8 0.6 0.6 1.4 0.1 0.4 0.3 0.2
95%
0.8 0.6 0.4 0.3 0.1 0.3 0.3 0.2
Percentile*
98% Percentile* 1.1 0.8 0.6 0.5 0.2 0.5 0.3 0.2
Statistical evaluation for samples separated depending on age and
gender
Gender male female
31 - 41 -
Age ≤ 30 41 - 50 51 - 60 ≥ 60 ≤ 30 31 - 40 51 - 60 ≥ 60
40 50
n 10 10 10 10 10 10 10 10 10 10
Parameter dsDNA
Median 0.3 0.3 0.3 0.2 0.3 0.3 0.3 0.3 0.2 0.3
Mean 0.3 0.3 0.4 0.2 0.3 0.4 0.5 0.3 0.3 0.4
SD 0.2 0.1 0.2 0.1 0.1 0.3 0.5 0.1 0.2 0.3
Mean + 2 SD 0.8 0.4 0.7 0.4 0.5 1.0 1.5 0.5 0.8 1.0

[Table 1 on page 5]
Sampl		New device (U/ml)							
	Target								
e		ds	U1	Sm	Ro	La	Scl	Cen	Jo
									
CDC
CDC
CDC 3
CDC 4
CDC 5
CDC 6
CDC 7
CDC 8
CDC 9
CDC	dsDNA & week Sm
SS-B/La
speckled pattern, U1RNP, SS-A/Ro,
U1-RNP
Sm
nucleolar pattern
SS-A/Ro
CenP
Scl-70
Jo-1	7.1
0.2
0.2
0.2
0.5
0.2
0.6
0.2
0.4
0.1	0.5
0.2
3.4
3.3	1.0
0.2
0.2
0.2
4.5
0.4
0.2
0.1
0.2
0.1	0.2
2.6
3.0
0.1
0.2
0.3
3.5
0.1
0.1	0.0
3.3
2.8
0.0
0.0
0.2
0.1
0.0
0.0
0.0	0.1
0.1
0.1
0.1
0.2
0.3
0.1
0.1
3.8
0.1	0.2
0.1
0.1
0.1
0.2
0.2
0.1
4.7
0.2
0.1	0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
4.2
			2.8						
			0.3
0.1
0.1
0.2
0.1						
					1.8				

[Table 2 on page 5]
Analyter	dsDNA	U1RNP	Sm	SS-A/Ro	SS-B/La	Scl-70	CENP	Jo-1
n	100	100	100	100	100	100	100	100
Median*	0.3	0.3	0.2	0.1	0.0	0.1	0.1	0.1
Mean*	0.3	0.3	0.2	0.2	0.0	0.1	0.2	0.1
SD*	0.2	0.2	0.2	0.6	0.1	0.1	0.1	0.0
Mean + 2 SD*	0.8	0.6	0.6	1.4	0.1	0.4	0.3	0.2
95%
Percentile*	0.8	0.6	0.4	0.3	0.1	0.3	0.3	0.2
98% Percentile*	1.1	0.8	0.6	0.5	0.2	0.5	0.3	0.2

[Table 3 on page 5]
Gender
Age
n	male
31 -
≤ 30 41 - 50 51 - 60 ≥ 60
40
10 10 10 10 10	female
41 -
≤ 30 31 - 40 51 - 60 ≥ 60
50
10 10 10 10 10
Parameter	dsDNA	

--- Page 6 ---
Gender male female
31 - 41 -
Age ≤ 30 41 - 50 51 - 60 ≥ 60 ≤ 30 31 - 40 51 - 60 ≥ 60
40 50
n 10 10 10 10 10 10 10 10 10 10
95%
0.7 0.4 0.7 0.4 0.4 0.9 1.3 0.5 0.7 0.9
Percentile
98%
0.8 0.4 0.8 0.4 0.4 1.0 1.6 0.5 0.7 1.0
Percentile
Parameter U1RNP
Median 0.2 0.2 0.3 0.3 0.3 0.3 0.2 0.3 0.3 0.3
Mean 0.2 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.4 0.4
SD 0.1 0.1 0.2 0.1 0.1 0.1 0.2 0.1 0.3 0.2
Mean + 2 SD 0.4 0.5 0.7 0.4 0.6 0.6 0.6 0.5 1.0 0.7
95%
0.4 0.5 0.6 0.4 0.5 0.5 0.6 0.5 0.9 0.6
Percentile
98%
0.4 0.5 0.8 0.4 0.6 0.5 0.6 0.5 1.0 0.6
Percentile
Parameter Sm[D]
Median 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Mean 0.2 0.3 0.2 0.2 0.2 0.2 0.2 0.4 0.2 0.2
SD 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.4 0.1 0.1
Mean + 2 SD 0.3 0.5 0.3 0.5 0.3 0.3 0.3 1.2 0.4 0.5
95%
0.3 0.5 0.3 0.4 0.3 0.3 0.3 1.0 0.3 0.4
Percentile
98%
0.4 0.6 0.3 0.5 0.3 0.3 0.3 1.3 0.4 0.5
Percentile
Parameter SS-A/Ro
Median 0.1 0.1 0.1 0.1 0.2 0.2 0.1 0.2 0.1 0.1
Mean 0.2 0.1 0.1 0.1 0.2 0.6 0.2 0.6 0.2 0.1
SD 0.1 0.0 0.0 0.0 0.0 1.3 0.1 1.4 0.1 0.1
Mean + 2 SD 0.3 0.2 0.2 0.2 0.3 3.2 0.4 3.3 0.4 0.2
95%
0.3 0.2 0.2 0.2 0.2 2.5 0.3 2.6 0.4 0.2
Percentile
98%
0.4 0.2 0.2 0.2 0.2 3.5 0.4 3.7 0.4 0.2
Percentile
Parameter SS-A/La
Median 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Mean 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0
SD 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0
Mean + 2 SD 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.3 0.0 0.1
95%
0.1 0.0 0.0 0.1 0.1 0.2 0.1 0.3 0.0 0.1
Percentile
98%
0.1 0.0 0.0 0.1 0.1 0.2 0.1 0.4 0.0 0.1
Percentile
Parameter Scl-70
Median 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
Mean 0.2 0.1 0.1 0.1 0.2 0.1 0.1 0.2 0.1 0.1
SD 0.1 0.0 0.0 0.0 0.2 0.1 0.1 0.2 0.0 0.1
Mean + 2 SD 0.3 0.2 0.2 0.2 0.6 0.3 0.3 0.6 0.2 0.4
95%
0.3 0.2 0.2 0.2 0.5 0.3 0.3 0.6 0.2 0.3
Percentile
98%
0.3 0.2 0.2 0.2 0.6 0.3 0.3 0.6 0.2 0.4
Percentile
Parameter CENP

[Table 1 on page 6]
Gender
Age
n	male
31 -
≤ 30 41 - 50 51 - 60 ≥ 60
40
10 10 10 10 10	female
41 -
≤ 30 31 - 40 51 - 60 ≥ 60
50
10 10 10 10 10
95%
Percentile
98%
Percentile	0.7 0.4 0.7 0.4 0.4
0.8 0.4 0.8 0.4 0.4	0.9 1.3 0.5 0.7 0.9
1.0 1.6 0.5 0.7 1.0
Parameter	U1RNP	
Median
Mean
SD
Mean + 2 SD
95%
Percentile
98%
Percentile	0.2 0.2 0.3 0.3 0.3
0.2 0.3 0.3 0.3 0.3
0.1 0.1 0.2 0.1 0.1
0.4 0.5 0.7 0.4 0.6
0.4 0.5 0.6 0.4 0.5
0.4 0.5 0.8 0.4 0.6	0.3 0.2 0.3 0.3 0.3
0.3 0.3 0.3 0.4 0.4
0.1 0.2 0.1 0.3 0.2
0.6 0.6 0.5 1.0 0.7
0.5 0.6 0.5 0.9 0.6
0.5 0.6 0.5 1.0 0.6
Parameter	Sm[D]	
Median
Mean
SD
Mean + 2 SD
95%
Percentile
98%
Percentile	0.2 0.2 0.2 0.2 0.2
0.2 0.3 0.2 0.2 0.2
0.1 0.1 0.0 0.1 0.0
0.3 0.5 0.3 0.5 0.3
0.3 0.5 0.3 0.4 0.3
0.4 0.6 0.3 0.5 0.3	0.2 0.2 0.2 0.2 0.2
0.2 0.2 0.4 0.2 0.2
0.1 0.1 0.4 0.1 0.1
0.3 0.3 1.2 0.4 0.5
0.3 0.3 1.0 0.3 0.4
0.3 0.3 1.3 0.4 0.5
Parameter	SS-A/Ro	
Median
Mean
SD
Mean + 2 SD
95%
Percentile
98%
Percentile	0.1 0.1 0.1 0.1 0.2
0.2 0.1 0.1 0.1 0.2
0.1 0.0 0.0 0.0 0.0
0.3 0.2 0.2 0.2 0.3
0.3 0.2 0.2 0.2 0.2
0.4 0.2 0.2 0.2 0.2	0.2 0.1 0.2 0.1 0.1
0.6 0.2 0.6 0.2 0.1
1.3 0.1 1.4 0.1 0.1
3.2 0.4 3.3 0.4 0.2
2.5 0.3 2.6 0.4 0.2
3.5 0.4 3.7 0.4 0.2
Parameter	SS-A/La	
Median
Mean
SD
Mean + 2 SD
95%
Percentile
98%
Percentile	0.0 0.0 0.0 0.0 0.0
0.0 0.0 0.0 0.0 0.0
0.0 0.0 0.0 0.0 0.0
0.1 0.1 0.1 0.1 0.1
0.1 0.0 0.0 0.1 0.1
0.1 0.0 0.0 0.1 0.1	0.0 0.0 0.0 0.0 0.0
0.1 0.0 0.1 0.0 0.0
0.1 0.0 0.1 0.0 0.0
0.2 0.1 0.3 0.0 0.1
0.2 0.1 0.3 0.0 0.1
0.2 0.1 0.4 0.0 0.1
Parameter	Scl-70	
Median
Mean
SD
Mean + 2 SD
95%
Percentile
98%
Percentile	0.1 0.1 0.1 0.1 0.1
0.2 0.1 0.1 0.1 0.2
0.1 0.0 0.0 0.0 0.2
0.3 0.2 0.2 0.2 0.6
0.3 0.2 0.2 0.2 0.5
0.3 0.2 0.2 0.2 0.6	0.1 0.1 0.1 0.1 0.1
0.1 0.1 0.2 0.1 0.1
0.1 0.1 0.2 0.0 0.1
0.3 0.3 0.6 0.2 0.4
0.3 0.3 0.6 0.2 0.3
0.3 0.3 0.6 0.2 0.4
Parameter	CENP	

--- Page 7 ---
Gender male female
31 - 41 -
Age ≤ 30 41 - 50 51 - 60 ≥ 60 ≤ 30 31 - 40 51 - 60 ≥ 60
40 50
n 10 10 10 10 10 10 10 10 10 10
Median 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
Mean 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.1 0.1
SD 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0
Mean + 2 SD 0.4 0.3 0.2 0.2 0.3 0.3 0.3 0.2 0.2 0.2
95%
0.3 0.3 0.2 0.2 0.2 0.3 0.3 0.2 0.2 0.2
Percentile
98%
0.4 0.3 0.2 0.2 0.2 0.3 0.3 0.2 0.2 0.2
Percentile
Parameter Jo-1
Median 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
Mean 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
SD 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0
Mean + 2 SD 0.3 0.1 0.2 0.2 0.1 0.3 0.2 0.2 0.1 0.2
95%
0.3 0.1 0.1 0.2 0.1 0.2 0.2 0.1 0.1 0.2
Percentile
99%
0.4 0.1 0.1 0.2 0.1 0.3 0.2 0.2 0.1 0.2
Percentile
Histogram
Histogram
100
90
80
70
60
50
40
30
20
10
0
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.1 1.2 1.3 1.4 1.5 more
Bin
]
%[
ycneuqerF
dsDNA
U1RNP
Sm
SS-A/Ro
SS-B/La
Scl-70
CENP
Jo-1
Ratio
2. Comparison studies:
Data presented are for SmD only.
a. Method comparison with predicate device:
i. Study design: Refer to the method comparison data in Varelisa
ReCombi ANA Profile (k993109) and Varelisa Sm Antibodies

[Table 1 on page 7]
Gender
Age
n	male
31 -
≤ 30 41 - 50 51 - 60 ≥ 60
40
10 10 10 10 10	female
41 -
≤ 30 31 - 40 51 - 60 ≥ 60
50
10 10 10 10 10
Median
Mean
SD
Mean + 2 SD
95%
Percentile
98%
Percentile	0.2 0.1 0.1 0.1 0.1
0.2 0.2 0.2 0.2 0.2
0.1 0.1 0.0 0.0 0.0
0.4 0.3 0.2 0.2 0.3
0.3 0.3 0.2 0.2 0.2
0.4 0.3 0.2 0.2 0.2	0.1 0.1 0.1 0.1 0.1
0.2 0.2 0.2 0.1 0.1
0.1 0.1 0.0 0.0 0.0
0.3 0.3 0.2 0.2 0.2
0.3 0.3 0.2 0.2 0.2
0.3 0.3 0.2 0.2 0.2
Parameter	Jo-1	
Median
Mean
SD
Mean + 2 SD
95%
Percentile
99%
Percentile	0.1 0.1 0.1 0.1 0.1
0.1 0.1 0.1 0.1 0.1
0.1 0.0 0.0 0.0 0.0
0.3 0.1 0.2 0.2 0.1
0.3 0.1 0.1 0.2 0.1
0.4 0.1 0.1 0.2 0.1	0.1 0.1 0.1 0.1 0.1
0.1 0.1 0.1 0.1 0.1
0.1 0.0 0.0 0.0 0.0
0.3 0.2 0.2 0.1 0.2
0.2 0.2 0.1 0.1 0.2
0.3 0.2 0.2 0.1 0.2

--- Page 8 ---
(k042629). Since the major difference between the new and predicate
device is Sm, a comparative study was performed between the SmD of
the new device and the Sm (B, B’, D) of the predicate device. The
new test was also compared to a semiquantitative test (k042629). One
hundred and eighty samples positive for at least one autoantibody and
20 samples from blood donors were analyzed in single determinations.
Calibrators and Controls were analyzed in duplicates. Results of both
comparisons are depicted in the tables below. Equivocal results were
regarded as negative.
Correlation of New and Predicate device
Predicate device
Sm
Positive Equivocal Negative Σ
Positive 16 3 8 27
New Equivocal 1 2 5 8
device Negative 5 1 159 165
Σ 22 6 172 200
Positive Agreement 72.7% (16/22)
Negative Agreement 93.8% (167/178)
Total Agreement 91.5% (183/200
Correlation of New Device and Semiquantitative test (K042629)
Semiquantitative test
Sm
Positive Equivocal Negative Σ
Positive 23 3 1 27
New Equivocal 0 2 6 8
device Negative 0 1 164 165
Σ 23 6 171 200
Positive Agreement 100% (23/23)
Negative Agreement 97.7% (173/177)
Total Agreement 98.0% (196/200)
b. Matrix comparison:
The Sm[D] study included the use of serum, heparin plasma, citrate plasma
and EDTA plasma. The conclusion of the study is that the use of heparin
interfered with the Sm antigen.
3. Clinical studies:
a. Clinical Sensitivity:
Not given.
b. Clinical specificity:
Not given.
c. Other clinical supportive data (when a. and b. are not applicable):
Not Applicable.
4. Clinical cut-off:
Refer to Assay cut-off.
5. Expected values/Reference range:
Refer to Assay cut-off.

[Table 1 on page 8]
16	3	8
1	2	5
5	1	159

[Table 2 on page 8]
23	3	1
0	2	6
0	1	164

--- Page 9 ---
N. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.
O. Conclusion:
The submitted information in this premarket notification is complete and supports a
substantial equivalence decision.